Regorafénib N-oxyde-d3 (M2)

Modify Date: 2024-01-31 21:16:53

Regorafénib N-oxyde-d3 (M2) Structure
Regorafénib N-oxyde-d3 (M2) structure
Common Name Regorafénib N-oxyde-d3 (M2)
CAS Number 1333489-03-4 Molecular Weight 501.83
Density N/A Boiling Point N/A
Molecular Formula C21H12D3ClF4N4O4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Regorafénib N-oxyde-d3 (M2)


Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

 Names

Name Regorafénib N-oxyde-d3 (M2)

 Regorafénib N-oxyde-d3 (M2) Biological Activity

Description Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.  

[2]. Allard M, et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2017 Aug 5;142:42-48.  

 Chemical & Physical Properties

Molecular Formula C21H12D3ClF4N4O4
Molecular Weight 501.83